BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 4
• 5
• 6
• 7
• 10
• 11
• 12
• 13
• 14
• 17
• 18
• 19
• 20
• 21
• 24
• 25
• 26
• 27
• 28

• Pharm Country

  Daxor Corporation Announces Filing of Form N-CSR for June 30, 2012 and Volumex Kit Sales for the First Six Months of 2012

  September 4, 2012

   · 

  1 min read
• Drug Development

  AVANIR Pharmaceuticals Announces Enrollment of First Patient in Study of AVP-923 for the Treatment of Agitation in Patients With Alzheimer’s Disease

  September 4, 2012

   · 

  7 min read
• Business

  AssayMetrics and Cambridge Research Biochemicals Collaborate in the Field of Fluorescence Lifetime Technology

  September 4, 2012

   · 

  2 min read
• Drug Development

  Boehringer Ingelheim Corporation Release: First Phase III Data for Tiotropium in Symptomatic Asthma Patients Treated With ICS/LABA Published in The New England Journal of Medicine

  September 4, 2012

   · 

  5 min read
• InDex Pharmaceuticals AB Strengthens IP Position for Kappaproct

  September 4, 2012

   · 

  3 min read
• Biotech Beach

  Data From Peregrine Pharmaceuticals, Inc.'s Phase II Bavituximab Second-Line Lung Cancer Trial to be Highlighted in Late-Breaking Oral Presentation at the 2012 Chicago Multidisciplinary Symposium in Thoracic Oncology

  September 4, 2012

   · 

  3 min read
• Pharm Country

  Sun Pharmaceutical Industries Ltd Issues Nationwide Voluntary Recall of One Lot of Nimodipine Capsules Due to Crystallization of the Fill Material

  September 4, 2012

   · 

  2 min read
• Pharm Country

  GBI Research Release: Patients Come First, as Pharma Companies Try to Please With Innovation in Drug Delivery

  September 4, 2012

   · 

  3 min read
• Biotage AB Unveils New Fully Automated Microwave Peptide Synthesizer

  September 4, 2012

   · 

  2 min read
• Pharm Country

  Soligenix Announces $300,000 National Cancer Institute SBIR Grant Award Supporting a Phase 2 Trial of orBec® as a Treatment for Chronic GI GVHD

  September 4, 2012

   · 

  7 min read